It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.
Aasems Jacob, MD
Advertisement
Articles by Aasems Jacob, MD
Advertisement
Latest Updated Articles
- Optimal Use of Bone-Targeted Agents in Breast Cancer
August 15th 2016
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5